Summarized by Masters of Longevity from Longevity Technology.
Early interim data showed clinical benefit signals in advanced liver disease patients.

Key Takeaways
- Nine patients were included in the interim readout.
- Engineered autologous macrophages are aimed at regeneration and antifibrosis.
- The findings are preliminary and have not established causal efficacy.



